問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Medical University Hospital (在職)

Division of Thoracic Medicine

Linkou Chang Gung Medical Foundation (在職)

Division of Thoracic Medicine

Division of Thoracic Surgery

Division of General Internal Medicine

更新時間：2023-09-19

郭漢彬Kuo, Han-Pin
  • Principal Investigator
  • Clinical Trial Experience (year) -23 years -3 個月

  • q8828@tmu.edu.tw

Recruiting Trial

19Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

郭漢彬

Taipei Medical University Hospital

Division of Thoracic Medicine

List

13Cases

2022-05-01 - 2026-03-31

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2018-11-02 - 2028-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

李岡遠
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Thoracic Medicine

郭漢彬
Taipei Medical University Hospital

Division of Thoracic Medicine

2023-04-01 - 2025-03-04

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2021-07-01 - 2023-06-30

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2025-10-01 - 2027-10-01

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2022-12-23 - 2026-12-31

Phase I/II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting2Sites

Recruiting4Sites

2021-04-06 - 2026-05-08

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting5Sites

Terminated3Sites

2020-06-20 - 2027-12-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
13Sites

Not yet recruiting3Sites

Recruiting9Sites

Terminated1Sites

2021-08-01 - 2023-07-31

Others

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2020-01-03 - 2021-03-08

Phase III

A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study of Efficacy and Safety of AR-301 as Adjunct Therapy to Antibiotics in the Treatment of Ventilator-associated Pneumonia (VAP) Caused by S. aureus

  • Condition/Disease

    AR-301 as Adjunct Therapy to Antibiotics in the Treatment of Ventilator-associated Pneumonia (VAP) Caused by S. aureus

  • Test Drug

    AR-301 Tosatoxumab

Participate Sites
10Sites

Not yet recruiting9Sites

Recruiting1Sites

1 2
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB